Dermatological Drugs Market Forecast 2016-2026

04 September 2016
Pharma

A new report by visiongain predicts that the Dermatological Drugs market will reach $39.25bn in 2026. This forecast and others appear in - Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma published in July 2016. Visiongain is a business information provider based in London, UK.
The Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma, report examines the current and future trends in the Dermatological Drugs Market with particular focus on recent pivotal developments in the sector including patent expiries, biosimilar approvals, patent invalidations, launch of new drugs and pipeline products. These developments in addition to changes in population demographics are changing the landscape of the dermatological drugs market.

Dermatological Drugs are used to treat and manage a wide variety of skin conditions from skin infections, dermatitis, psoriasis and acne. These dermatological diseases are very common, leading to a large patient population.

The driving force behind growth in this market is the high unmet clinical need for dermatological conditions, a healthy pipeline of development-stage products and new products launching onto the market as well as advances in drug delivery options. As the global population ages there is an increased demand for treatment of intermittent or long-standing conditions, in addition to an increased demand from populations in both emerging and developed economies to improve skin care and health. The highly fragmented dermatological drugs market is increasingly expected to innovate in order to meet these demands in a safe manner. Pipeline development of biologics and personalised dermatology treatments with more sophisticated technologies to improve drug delivery formulations, safety and efficacy are anticipated to be the next paradigm shift in the dermatological drugs market.

In this report, we examine in detail the factors which are driving growth in the Dermatological Drugs Market, the key companies currently operating in the market including their product pipelines. We also examine key national markets and discuss trends and variations within these markets, alongside an analysis of dermatological drugs.
The Dermatological conditions examined in this report are: Psoriasis, Skin Infections, Acne and Dermatitis. National Markets focused on are the US, China, Japan, EU5 (Germany, UK, Italy, France and Spain), Brazil, Russia and India.

Using both primary and secondary research, forecasts have been built for the major submarkets, leading products and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Visiongain’s report also provides an analysis of the current leading players in the Dermatological Drugs Market. Historical financial performance is analysed, along with a breakdown of each company’s leading products and pipeline research, and recent merger & acquisition information, with an analysis of news that may influence the course of the company.

Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever